ClinicalTrials.gg
TerminatedNCT04218773PRESSUpdated Oct 14, 2026

Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study

An Early Phase 1 interventional study of Phenylephrine and Norepinephrine in Ischemic Stroke and Blood Pressure, sponsored by Yale University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Yale University · Early Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated prematurely due to lack of continued funding.

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.
Updated Oct 14, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
294th of 364
15 · median 65
Started
2020
with 16 others
Phase 1
37 of 480
4 open now
Registered
264th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 294th largest by enrollment of the 364 interventional ones that give a count, is one of 17 that started in 2020, is one of 37 in phase 1, and was the 264th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

An open label, prospective, single center, pilot trial to assess feasibility and tolerability of short term blood pressure augmentation to minimize infarct progression in acute LVO stroke patients undergoing endovascular therapy.

Read the detailed description

The trial is planned to include 40 subjects with acute LVO stroke who meet the eligibility criteria. In stage 1 of the study, the investigators will monitor beat-to-beat blood pressure and other hemodynamic parameters in 20 patients receiving standard of care therapy. For the second stage, the investigators will enroll an additional 20 patients who will receive blood pressure augmentation therapy using intravenous fluids and phenylephrine or norepinephrine infusion. The investigators will increase baseline systolic blood pressure by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The study will assess how quickly a target blood pressure can be reached in the acute stroke setting, and furthermore the ability to successfully maintain these blood pressure targets throughout the intervention and avoid hypotension during conscious sedation or general anesthesia. The primary research hypothesis of the trial is that treatment failure defined as an inability to achieve and maintain blood pressure targets despite the use of maximum tolerable doses of vasopressors (phenylephrine or norepinephrine) occurs in less than 20% of cases. In addition, the study will evaluate the recruitment feasibility and preliminary safety of blood pressure augmentation.

03

Conditions studied

  • Ischemic Stroke
  • Blood Pressure

Browse trials for

Keywords

  • Induced hypertension
  • Blood pressure augmentation
  • Large-vessel occlusion
  • Thrombectomy
  • Endovascular therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age is ≥18 years
  2. Patients presenting with anterior circulation acute ischemic stroke
  3. Enrollment within 24 hours of stroke onset
  4. Treatment with endovascular thrombectomy
  5. Arterial occlusion on CTA or MRA of the ICA, M1 or M2
  6. Mismatch - Using CT or MRI with a Tmax >6 second delay perfusion volume and either CT-rCBF or DWI infarct core volume.

    1. Mismatch ratio of greater than 1.8, and
    2. Absolute mismatch volume of greater than 15 ml, and
    3. Infarct core lesion volume of less than 70 mL

Exclusion criteria

Exclusion Criteria:

  1. Baseline SBP>200 mm Hg
  2. Intracranial hemorrhage (ICH) identified by CT or MRI
  3. Inability to access the cerebral vasculature in the opinion of the neurointerventional team
  4. to imaging with MR
  5. A history of a left ventricular heart failure ( Class ≥ III, or EF \< 50%) or angina (either unstable or CCS Grade II) involving symptoms at rest or with ordinary physical activity
  6. Acute myocardial infarction in the past 6 months
  7. Signs or symptoms of acute myocardial infarction, including find-ings, on admission
  8. Elevated serum troponin concentration on admission (>0.1 μg/L)
  9. Suspicion of aortic dissection on admission
  10. Participation in any study in the previous 30 days
  11. Treatment with Monoamine oxidase inhibitors (MAO-I) within last 7 days
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Induced hypertension

    The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.

    Drug: Phenylephrine · Drug: Norepinephrine

Interventions

  • Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.

    Also known as: Neo-Synephrine

  • As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.

    Also known as: Levophed

06

What researchers measure

Primary outcomes

  1. Primary Feasibility Outcome: Ability to achieve and maintain systolic blood pressure goals

    Percentage of treatment success is defined as the percentage of patients able to achieve target blood pressure within 60 minutes and maintain it throughout the procedure.

    Time frame: Through completion of the thrombectomy procedure, an average of 2.5 hours

  2. Primary Safety Outcome: Number of patients with symptomatic intracranial hemorrhage

    Symptomatic intracerebral hemorrhage (sICH) is defined per SITS-MOST criteria as local or remote parenchymal hemorrhage type 2 on the post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline, or from the lowest NIHSS value between baseline and 24 h, or leading to death.

    Time frame: 72 hours

Secondary outcomes

  1. Total number of serious adverse events

    Number of treatment-related SAEs including but not limited to myocardial infarction, congestive heart failure and death during the first 24 hours from enrollment. Any SAE judged probably or definitely related to the study treatment is counted as a treatment-related SAE. The timeframe for SAE is based on the rapid onset and short half-life of phenylephrine and norepinephrine. Late SAEs are not expected to be related to treatment; however, these SAEs also are ascertained.

    Time frame: 24 hours

Other outcomes

  1. Recruitment feasibility: Rate of patient identification

    Rate of patient identification will be calculated as the number of eligible patients who were identified and approached for consent by the study team divided by the number of eligible patients.

    Time frame: Though study completion, an average of one year

  2. Recruitment feasibility: Rate of consent

    Patient rate of consent will be calculated as the number of eligible patients who provided consent for participation divided by the total number of eligible patients.

    Time frame: Though study completion, an average of one year

  3. Recruitment feasibility: Enrollment rate

    Patient enrollment rate will be calculated as enrolled patients per month.

    Time frame: Though study completion, an average of one year

  4. Recruitment feasibility: Time to enrollment

    Time to enrollment will be assessed by calculating the time from ED presentation to enrollment in the study.

    Time frame: Though study completion, an average of one year

07

Study locations

1 site
  • Yale-New Haven Hospital
    New Haven, Connecticut 06510, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2020 to primary completion in Jun 2022, 21 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jun 2022, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2019
First posted
Jan 6, 2020
StartActual
Sep 11, 2020
Primary completionActual
Jun 30, 2022was Aug 2026
CompletionActual
Aug 31, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated The study was terminated prematurely due to lack of continued funding.
changed Oct 14, 2026
Primary completion
Aug 2026→Jun 30, 2022 (actual)
Oct 14, 2026
Enrollment
40 (estimated)→15 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Suspended→Terminated
    Why stopped The study was terminated prematurely due to lack of continued funding.
    Primary completion Aug 2026→Jun 30, 2022 (now actual)
    Enrollment 40 (estimated)→15 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04218773
Lead sponsor
Yale University
Responsible party
Nils Petersen (Assistant Professor of Neurology, Yale University) — Principal investigator
First posted
Jan 6, 2020
Start date
Sep 11, 2020
Primary completion
Jun 30, 2022
Completion
Aug 31, 2026
Last update
Oct 14, 2026

Study contacts

Nils H Petersen, MD, MSc
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Phenylephrine · Norepinephrine

Start the discussion